In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...

Health Canada authorized Novavax's updated COVID-19 vaccine that protects against currently circulating variants of the virus ...

COVID-19 vaccine-associated myocarditis (C-VAM) has a mild initial clinical course, but myocardial injury is common, ...

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $75.00. The ...

Shares of Moderna Inc. MRNA slipped 2.63% to $68.02 Thursday, on what proved to be an all-around favorable trading session ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $69.86 which represents a decrease of $-2.13 or -2.96% from the prior close of $71.99. The stock opened at $72.19 and touched a low of $69.82 ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and ...

GILD Stock Soars on HIV Drug Data: Gilead’s shares gained after the company announced upbeat results from an interim analysis of a second late-stage study evaluating the use of the company’s ...

With the U.S. Food and Drug Administration and Centers for Disease Control and Prevention approval of new mRNA COVID-19 ...

2 [Alt text] From left to right, the figure outlines key elements of posttranscriptional pre-mRNA splicing: an RNA transcript (pre-mRNA) displaying introns and exons, and six common splicing ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...